PDCD1 and neoplasm: Clinical data from CodeBreak 100/101 revealed promising efficacy with long-lasting anti-tumor effects when a programmed cell death protein 1 (PD-1) antibody was administered alongside a KRASG12C inhibitor, suggesting that PD-1 inhibition produces a synergistic effect with sotorasib and enhances CD8-positive T-cell infiltration, which causes an inhibition of tumor growth [83–87].